ADCC Assay Services Quotation Form



Instructions

|1. Please read and complete the form carefully due to the complexity of the immune cell stimulation and cytokine release assay |

|2. Please email the completed form to bioassay@ |

|3. Our service representative will contact you as soon as possible |

Customer Information

|Name:           |

|Phone:           |

|Institution/Company:           |

|Shipping address:           |

|Email:           |

Immune Cell Stimulation and Cytokine Release Assay Service (SC-1589)

|Do you need a monoclonal antibody as the positive control? |

|Yes, I need. I will provide the antibody. |

|Yes, I need. But I don’t have the antibody. |

|No, I don’t need. |

|Note: |

|1. Positive control antibodies, which are produced according to the published sequences and functionally validated in-house, are available at GenScript. A |

|list is provided in the Appendix at the end of this form. |

|2. Positive control antibodies provided by GenScript will NOT be charged for the assay service, whereas client’s positive controls will be treated as |

|samples. |

|Number of Test Antibodies:            |

|Note: |

|GenScript’s positive and negative controls are not included if inclusion of control antibody is applicable. |

|Nature of Test Antibodies: |

|Human; Mouse; Human & Mouse Chimeric; Fc fusion protein; Others:           ; |

|IgG1; IgG2; IgG3; IgG4; Others:            |

| |

|Note: |

|Selection of antibody class will help us to decide what negative control to be included in the assay, e.g. if your antibody sample belongs to IgG4 class, an|

|irrelevant human IgG4 antibody will be used as the negative control. |

|Name of Target Molecule:       |

| |

|Note: |

|If the name of the target molecule cannot be disclosed at this stage, please leave it blank. |

|Name of Effector Cells:       |

|CD3+ T cells; CD4+ T cells; CD8+ T cells; |

|Monocytes; NK cells; Dendritic Cells; Monocyte-Derived Macrophages; |

|PBMCs; Whole blood; Other, please specify:            |

|Stimulator Options: |

|PHA; PMA + Ionomycin; LPS; Anti-CD3 antibody (OKT3); |

|Anti-CD3/Anti-CD28 beads; Superantigen (e.g. SEA, SEB, SEE, etc.), please specify:            ; |

|Dendritic Cells; Raji cells; Other tumor cell lines, please specify:            |

|Other stimulating factors (e.g. cytokines, small molecules, etc., please specify:            |

|Co-factors: |

|Please specify other co-factors to be added in the stimulation experiment if there is any: |

|a. Co-factor 1:           , immune stimulation; immune suppression; unknown; |

|b. Co-factor 2:           , immune stimulation; immune suppression; unknown; |

|c. Co-factor 3:           , immune stimulation; immune suppression; unknown; |

|Immune Cell Stimulating Conditions: |

|a. Effector cell seeding density:           cells/well (96-well plate); |

|Optimization required; Use GenScript’s default value, obtained from past experience; |

|b. Serum concentration:           %; |

|Optimization required; Use GenScript’s default value, obtained from past experience; |

|c. Duration of stimulation:           hrs; |

|Optimization required; Use GenScript’s default value, obtained from past experience; |

|d. Concentration of stimulator:           ng/ml or cells/well |

|Optimization required; Use GenScript’s default value, obtained from past experience; |

|e. Concentration of co-factor 1:            |

|Optimization required; |

|f. Concentration of co-factor 2:            |

|Optimization required; |

|g. Concentration of co-factor 3:            |

|Optimization required; |

|Parameters to be assessed: |

|IL-2; IFN-γ; TNFα; GM-CSF; Other, please specify:           ; |

|Multiplex Cytokine Release Assay (Luminex), |

|please specify the cytokine collection:           ; |

|please specify the link to the kit if it is already available:           ; |

|Multiplex Cytokine Release Assay (MSD), |

|please specify the cytokine collection:           ; |

|please specify the link to the kit if it is already available:           ; |

|Dose-response Curve: |

|8 doses (including 0 ug/ml) in triplicate. |

|Starting concentration by default: 10 μg/ml; dilution factor: 3; |

|Customized starting concentration:            μg/ml; dilution factor:            |

|Optimization is required. |

|Assessment of Antigen Expression Level of Target Cell by FACS: |

|Yes, I need. If “Yes” is selected, please provide the name of the target:       |

|No, I don’t need. |

| |

|Note: |

|If “No” is selected, the customer needs to provide evidence of target expression on the target cells. |

|Please specify any other special requirements: |

|                     |

Project Information

|Is this project for grant application purpose? Yes No |

|When will the project start? Immediately Within one month Within three months Half a year later |

Note: Final report contains raw data, processed data, protocol summary, dose-response curve and EC50 value for each antibody sample.

Appendix

List of positive control antibodies available at GenScript, which are produced in-house according to their published sequences.

Anti-CD40 agonist antibody

Anti-OX40 agonist antibody

Anti-GITR agonist antibody

Anti-4-1BB agonist antibody

Hu-5F9-G4 (anti-CD47)

IMAB362 (anti-Claudin 18.2)

IMAB027 (anti-Claudin 6)

Tecentriq (anti-PD-L1)

Keytruda (anti-PD-1)

Opdivo (anti-PD-1)

25F7 (anti-LAG3)

OSE172 (anti-Sirpα)

NC318 (anti-Siglec-15)

Yervoy (anti-CTLA-4)

22G2 (anti-TIGIT)

Siltuximab (anti-IL-6)

F7-G4 (anti-CXCR4)

Rituxan (anti-CD20)

Herceptin (anti-Her2)

Humira (anti-TNFα)

Erbitux (anti-EGFR)

Darzalex (anti-CD38)

-----------------------

Immune Cell Stimulation and Cytokine Release Assay Service Quotation Form

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download